Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

Video

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Karim Chamie, MD, associate professor, Urology, UCLA Health, discusses the design of the phase 2/3 QUILT-3.032 trial (NCT0302282) in patients with Bacillus Calmette-Guerín (BCG)–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

BCG-unresponsive bladder cancer is not a disease that is common, and because of this, the FDA approves drugs that have achieved certain milestones, according to Chamie. For example, phase 3 trials where patients are randomized to placebo or the study drug are not necessary in the patient population. Instead, the FDA has allowed companies to develop single-arm studies in which every patient receives the investigational agent, Chamie adds.

As such, in the single-arm QUILT-3.032 study, every patient received N-803 plus BCG, Chamie concludes. At the 2021 AUA Annual Meeting, data from the interim analysis of cohort A of the trial, which was comprised of patients with BCG-unresponsive NMIBC carcinoma in situ (CIS). The primary end point of this cohort was incidence of complete response of CIS at any time, and it was met.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Daniel Petrylak, MD
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania